Medication reconciliation role and value in Alzheimer's disease treatment

被引:0
|
作者
Shen, Xueqian [1 ]
Zhang, Qun [2 ]
Shao, Wenliang [1 ]
Shi, Jianying [1 ]
Liu, Bing [2 ]
机构
[1] Second Hosp Jinhua, Dept Pharm, Jinhua, Zhejiang, Peoples R China
[2] Second Hosp Jinhua, Dept Wards Geriatr 5, Jinhua, Zhejiang, Peoples R China
关键词
Medication Reconciliation; Alzheimer Disease; Safety; Drug-Related Side Effects and Adverse Reactions; IMPACT;
D O I
10.1590/0004-282X-ANP-2021-0147
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: With the continuous increase of Alzheimer's disease (AD), it is also imminent to treat patients with AD for medication reconciliation. Objective: To explore the role and value of medication reconciliation in AD treatment. Methods: 100 patients over 65 years of age diagnosed with AD were randomly separated into two groups: conventional treatment and medication reforming. The list of medical orders of all subjects was obtained within 24 hours after admission with Beers criteria, STOPP/START criteria, and Chinese Pharmacopoeia used as the MED intervention criteria. Medication reconciliation was performed at 2 weeks, 1 month, and 2 months after hospital admission. The number of medications prescribed, the quantity of the medication, medication error rate, therapeutic effect, adverse drug reactions, and satisfaction levels of family members and main caregivers were compared between the two groups. Results: After the intervention, the types and amount of medication in the MED group were less compared to the CON group along with a reduced medication deviation rate. The Mini-mental state examination (MMSE) score and the proportion of well-nourished patients in the MED group were higher than those in the CON group. It was also observed that the physical self-care ability score and the proportion of patients with abnormal swallowing were lower when in comparison with the CON group. The incidence of adverse drug reactions in the MED group was lower than that in the CON group. However, the satisfaction rate was higher than that in the CON group. Conclusion: Medication reconciliation can reduce the medication deviation in AD patients.
引用
收藏
页码:233 / 239
页数:7
相关论文
共 50 条
  • [41] Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease
    T. Heinen-Kammerer
    H. Rulhoff
    S. Nelles
    R. Rychlik
    Clinical Drug Investigation, 2006, 26 : 303 - 314
  • [42] Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease
    Heinen-Kammerer, T.
    Rulhoff, H.
    Nelles, S.
    Rychlik, R.
    CLINICAL DRUG INVESTIGATION, 2006, 26 (06) : 303 - 314
  • [43] Role of Apolipoprotein E in Alzheimer's Disease Pathogenesis, Prognosis and Treatment
    Reiss, Allison B.
    Housny, Mary
    Gulkarov, Shelly
    Hossain, Tahmina
    Locke, Brandon
    Srivastava, Ankita
    Pinkhasov, Aaron
    Gomolin, Irving H.
    Wisniewski, Thomas
    De Leon, Joshua
    DISCOVERY MEDICINE, 2024, 36 (189) : 1917 - 1932
  • [44] Role of hydrogen peroxide in the aetiology of Alzheimer's disease - Implications for treatment
    Milton, NGN
    DRUGS & AGING, 2004, 21 (02) : 81 - 100
  • [45] The role of insulin resistance in the pathogenesis of Alzheimer's disease - Implications for treatment
    Watson, GS
    Craft, S
    CNS DRUGS, 2003, 17 (01) : 27 - 45
  • [46] The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer's Disease Treatment
    Knight, Emily
    Geetha, Thangiah
    Broderick, Tom L. L.
    Babu, Jeganathan Ramesh
    METABOLITES, 2023, 13 (03)
  • [47] Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
    Lombardo, Sylvia
    Maskos, Uwe
    NEUROPHARMACOLOGY, 2015, 96 : 255 - 262
  • [48] The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer’s disease
    Siobhán McGettigan
    Yvonne Nolan
    Subrata Ghosh
    Denis O’Mahony
    European Geriatric Medicine, 2023, 14 : 913 - 917
  • [49] Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer's Disease
    Xiao, Xuewen
    Liu, Xixi
    Jiao, Bin
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [50] The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence
    Tousi, Babak
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 311 - 315